Avalon GloboCare Corp
ALBT
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.26M
Close$
$0.03
90.9% downside
Current Fair Value
90.9% downsideOvervalued by 90.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.26 Million |
|---|---|
| Enterprise Value | $4.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.64 |
| Beta | -0.05 |
| Outstanding Shares | 8,963,998 |
Return
| Return on Equity | -165.59% |
|---|---|
| Return on Assets | -119.50% |
| Return on Invested Capital | -196.77% |
Valuation & Multiples
| P/E Ratio | -0.16 |
|---|---|
| PEG | -0.21 |
| Price to Sales | - |
| Price to Book Ratio | 0.35 |
| Enterprise Value to Revenue | 6.63 |
| Enterprise Value to EBIT | -0.2 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.06%▲ 1.86% |
|---|---|
| Total Invested | $280,287▲ 127.51% |
| Investors Holding | 20▲ 6.00% |
ESG Score
No data
About Avalon GloboCare Corp
7 employeesAvalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 rela...